Rasco, D., Middleton, M., Gonzalez, R., Corrie, P., Pavlick, A., Lorigan, P., Plummer, R., Gore, M., Herbert, C., Agarwala, S., Logan, T., Khleif, S., Papadopoulos, K., Rangachari, L., Suri, A., Xu, Q., Kneissl, M., Bozón, V., & Olszanski, A. (n.d.). 300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. European journal of cancer, 51(3), S53–S54. http://access.bl.uk/ark:/81055/vdc_100051431864.0x00002b